A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumours

BACKGROUND: Two strategies to interrogate the insulin growth factor 1 receptor (IGF-1R) pathway were investigated: vertical inhibition with dalotuzumab and MK-2206 or ridaforolimus to potentiate PI3K pathway targeting and horizontal cross-talk inhibition with dalotuzumab and MK-0752 to exert effects...

Descripción completa

Detalles Bibliográficos
Autores principales: Brana, I, Berger, R, Golan, T, Haluska, P, Edenfield, J, Fiorica, J, Stephenson, J, Martin, L P, Westin, S, Hanjani, P, Jones, M B, Almhanna, K, Wenham, R M, Sullivan, D M, Dalton, W S, Gunchenko, A, Cheng, J D, Siu, L L, Gray, J E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2014
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4229637/
https://www.ncbi.nlm.nih.gov/pubmed/25290091
http://dx.doi.org/10.1038/bjc.2014.497

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4229637/
https://www.ncbi.nlm.nih.gov/pubmed/25290091
http://dx.doi.org/10.1038/bjc.2014.497

Ejemplares similares